Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

Biochem Soc Trans. 1997 May;25(2):705-8. doi: 10.1042/bst0250705.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, CD / immunology
  • Antigens, CD20 / immunology
  • B-Lymphocytes / immunology
  • Clinical Trials, Phase II as Topic
  • Complement Activation
  • Cytotoxicity, Immunologic
  • Humans
  • Lymphoma, B-Cell / immunology
  • Lymphoma, B-Cell / therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Antigens, CD20
  • Rituximab